2024-01-31 14:23:35 ET
Summary
- Myriad Genetics demonstrates strong year-over-year growth in testing volumes and revenue in various segments of genetic testing.
- The company shows good management of costs and adjusts its revenue guidance, reflecting confidence in continued growth.
- Myriad Genetics strategically acquires assets to strengthen its operational efficiencies and position in oncology precision medicine.
In the field of genetic testing and precision medicine, Myriad Genetics (NASDAQ: MYGN ) is a progressive company, which can be observed in its steady double-digit revenue growth and the upward revision of revenue guidance for the next year. The financial results of the third quarter of 2023 of the company demonstrate a strong year-over-year growth in testing volumes in various segments, such as hereditary cancer, pharmacogenomics, and prenatal testing. This upward trend is not a temporary increase but the fifth quarter in a row of such results, which confirms the company's ability to manage growth given its current financials....
Read the full article on Seeking Alpha
For further details see:
Myriad Genetics' Strategic Growth Fuels Bullish Outlook